<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01422096</url>
  </required_header>
  <id_info>
    <org_study_id>CBS007</org_study_id>
    <secondary_id>CBS007</secondary_id>
    <nct_id>NCT01422096</nct_id>
  </id_info>
  <brief_title>Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess</brief_title>
  <official_title>Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS007)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test whether short-term suppression of ovarian function can ameliorate
      androgen (male hormone) overproduction in overweight girls with androgen excess. The
      investigators hypothesize that one dose of depot leuprolide agonist administration will
      improve androgen levels in girls with ovarian androgen overproduction. Specifically, this
      intervention will improve androgen levels after ovarian stimulation testing with recombinant
      human chorionic gonadotropin (rhCG).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>17 hydroxyprogesterone responses to rhCG before and 4 weeks after depot leuprolide administration</measure>
    <time_frame>4 weeks after leuprolide</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ovarian hormone precursor responses to rhCG before and 4 weeks after depot leuprolide administration</measure>
    <time_frame>4 weeks after leuprolide</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hyperandrogenemia</condition>
  <condition>Obesity</condition>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>leuprolide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>leuprolide 11.25 mg IM with adrenal suppression/stimulation testing with dexamethasone/Cortrosyn and ovarian stimulation testing with r-hCG before and 3 weeks after injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide</intervention_name>
    <description>depot leuprolide 11.25 mg if less than or equal to 37.5 kg or 15 mg if &gt; 37.5 kg im once</description>
    <arm_group_label>leuprolide</arm_group_label>
    <other_name>Depot Lupron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  overweight (&gt;85th BMI%) females

          -  Early to late puberty (expected age range 7-18)

          -  Hyperandrogenemic (free testosterone greater than 2.5 standard deviations above the
             mean for normal control subjects of the same Tanner Stage)

          -  Screening labs within age-appropriate normal range, with the exception of a mildly low
             hematocrit (see below) and the hormonal abnormalities inherent in obesity which could
             include mildly elevated luteinizing hormone (LH), lipids, testosterone, prolactin,
             DHEAS, E2, glucose, and insulin and decreased follicle-stimulating hormone (FSH)
             and/or sex hormone-binding globulin (SHBG)

        Exclusion Criteria:

          -  Screening labs outside of age-appropriate normal range

          -  Hemoglobin &lt;12 mg/dL and hematocrit&lt;36% (Subjects will be offered the opportunity to
             take iron supplementation for 60 days if their hematocrit is slightly low (33-36%)
             (suggestive of iron deficiency anemia) and will then return for retesting of their
             hemoglobin/hematocrit. If still &lt;36%, they will be excluded.)

          -  Morning Cortisol &lt;5 g/dL

          -  17-hydroxyprogesterone &gt;295 ng/dL

          -  History of Cushing's syndrome or adrenal insufficiency

          -  Pregnant
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine M. Burt Solorzano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deborah Sanderson</last_name>
    <phone>434-243-6911</phone>
    <email>pcos@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine M. Burt Solorzano, MD</last_name>
    <phone>434-243-6911</phone>
    <email>pcos@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia Center for Research in Reproduction</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deborah Sanderson</last_name>
      <phone>434-243-6911</phone>
      <email>pcos@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Christine M. Burt Solorzano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John C. Marshall, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2011</study_first_submitted>
  <study_first_submitted_qc>August 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2011</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Christine Burt Solorzano</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Hyperandrogenism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

